Page 472 - 16Neonatal Jaundice_compressed

Appendix H: Evidence tables

Bibliographic Study Type & Number of Intervention & Comparison Dichotomous outcomes Continuous Outcomes Comments
Information Evidence Level Patients/Characteristics (E:C) (Mean:SD: N)
2005 Not reported Term, breastfed babies, Phototherapy + Clofibrate
TsB between 291 and
Country: Randomisation: 512micromol/litre Clofibrate was administered in a single Mean duration of treatment:
Iran Random numbers oral dose (100 mg/kg) Group 1: 54 ± 18.8 hours
table Exclusion:
213
ID: Congenital anomaly, Group 2: 30 ± 12.9 hours
Evidence level: Haemolytic disease,
1 + Dehydration,
G6PD deficiency,
Conjugated
hyperbilirubinaemia

Demographics:
Gender (M/F):34/26
Mean GA: 38.7 ± 0.9 weeks
Mean BW: 3259 ± 481 g
Age at entry to study:
216 ± 94.8 hours
Mean TSB:
395 ± 58 micromol/litre
Author: Methodology: N: Group 1: No adverse effects were Mean decrease in TSB:
Zahedpasha Y RCT 60 Phototherapy + Placebo noted Group 1: -108 ± 24 micromol/litre

Year: Blinding: Inclusion: Group 2: Group 2: -148 ± 20 micromol/litre
2007 No reported Gestational age between 38 Phototherapy + Clofibrate
and 41 weeks,
Country: Randomisation: TsB between 256 and Subject in the clofibrate group received a
Iran Not reported 427micromol/litre single oral dose of clofibrate (100 mg/kg
body weight) while the control group
215
ID: Evidence level: Exclusion: received distilled water in the same
1 - Haemolytic disease, Rh or amount and colour.
ABO incompatibility,
G6PD deficiency,
dehydration,
Infection,
Conjugated
hyperbilirubinaemia,
History of Phenobarbital
intake by mother or infant

Demographics:
Gender (M/F): 28/32
Mean GA: Not reported
Mean BW: Not reported
Age at entry to study:
144 ± 71 hours

309